Potential Long Trade on CURE if FDA Reverses

about 1 month ago

"I think the FDA will chicken out and give them approval. And in some ways, this is almost a good thing for them because now it forces the issue since the stock was at 60 before and it was still like 50/50 what the FDA would do. So like now if the FDA changes their mind, we kind of should be going to 100 plus. And I think the FDA will change their mind. So it's kind of a great long. I still might buy some up here. It's up here and down here at the same time."

The speaker outlines an actionable trade call on CURE, suggesting that if the FDA reverses its current stance, the stock—which had been trading around 60—could surge above 100. The speaker expresses high conviction in a favorable FDA decision and indicates a readiness to accumulate on any price dislocation.

Related Stocks